Abstract
Since there is chronic hyperglycaemia in diabetes, there is an acceleration of the Maillard or browning reaction [1]. This is a spontaneous reaction between glucose and proteins, lipids or nucleic acids, particularly on long-lived proteins such as the collagens [1]. There is a sequence of biochemical reactions, many of which are still poorly defined, leading to the formation of a range of advanced glycation end-products (AGEs), some of which are fluorescent. These modified long-lived tissue proteins are formed as a result not only of glycation but also oxidative processes and many of these AGEs are now considered glycoxidation products [2]. Over the last decade, an increasing number of AGEs have been identified [3]. However, the identity of the AGEs linked to diabetic complications and in particular to renal disease has not been clearly determined. Of particular interest is the hypothesis that diet derived AGEs may also be involved in tissue AGE accumulation [4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836–841.
Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676–683.
Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, Zyzak DV, Thorpe SR, Baynes JW. New biomarkers of maillard reaction damage to proteins. Nephrol Dial Transplantation 1996; 11(Suppl 5): 41–47.
Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins) — an environmental risk factor in diabetic nephropathy. Proc Natl Acad USA 1997; 94: 6474–6479.
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629–1632.
Nicholls K, Mandel T. Advanced glycosylation end products in experimental murine diabetic nephropathy: effect of islet grafting and of aminoguanidine. Lab Invest 1989; 60: 486–489.
Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328–1334.
Hammes H, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555–11558.
Monnier V, Vishwanath V, Frank K, Elmets G, Dauchot P, Kohn R. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403–408.
Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463–2469.
Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836–842.
Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519–1522.
Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 1996; 50: 627–634.
Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam B, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997; 40: 619–628.
Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824–829.
Schmidt A, Vianna M, Gerlach M, Brett J, Ryan J, Kao C, Esposito H, Hegarty W, Hurley W, Clauss M, Wang F, Pan Y, Tsang T, Stern D. Isolation and characterisation of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987–14997.
Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395–1403.
Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238–243.
Li Y, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H. Molecular identity and distribution of advanced glycation endproducts receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047–11052.
Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Medicine 1995; 1: 1057–1061.
Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney International 1999; 55: 907–916.
Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436–9440.
Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704–11708.
Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert R. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 1997; 99: 1016–1027.
Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. J Biol Chem 1997; 272: 8723–8730.
Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219–1224.
Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA, Cooper ME. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78: 1017–1027.
Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Kelly DJ, Bach LA, Gilbert RE. Increased renal expression of VEGF and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229–2239.
Gilbert RE, McNally PG, Cox A, Dziadek M, Rumble J, Cooper ME, Jerums G. SPARC Gene Expression is Reduced in Early Diabetes Related Kidney Growth. Kidney Int 1995; 48: 1216–1225.
Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597–2601.
Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107–6111.
Kochakian M, Manjula BN, Egan JJ. Chronic dosing with aminoguanidine and novel advanced glycosylation end product formation inhibitors ameliorates cross-linking of tail tendon collagen in streptozotocin-induced diabetic rats. Diabetes 1996; 45: 1694–1700.
Soulis T, Sastra S, Thallas V, Mortensen SB, Wilken M, Clausen JT, Bjerrum OJ, Petersen H, Lau J, Jerums G, Boel E, Cooper ME. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 1999; 42: 472–479.
Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275–278.
Wolffenbuttel BHR, Boulanger CM, Crijns FRL, Huijberts MSP, Poitevin P, Swennen GNM, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Aced Sci USA 1998; 95: 4630–4634.
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26: 875–888.
Wuerth J-P, Bain R, Mecca T, Park G, Cartwright K, Pimagedine Investigator Group. Baseline data from the Pimagedine Action trials. Diabetologia 1997; 40(Suppl 1): A548.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cooper, M.E., Jerums, G. (2000). Advanced Glycation End-Products and Diabetic Renal Disease. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4499-9_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4499-9_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7028-4
Online ISBN: 978-1-4615-4499-9
eBook Packages: Springer Book Archive